For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Prior Assessment Consultation System Started on Full Scale April 1
April 11, 2011
- DSP Licenses Anti-MRSA Drug from Takeda
April 11, 2011
- New Subsidiary in Slovenia to Manage Business in SE Europe: Astellas
April 11, 2011
- AZ Appeals to Tokyo High Court in Iressa Affair
April 11, 2011
- DSP Licenses INT-747 from Intercept
April 11, 2011
- Sandoz K.K. Begins Importing Substitute for Thyradin
April 11, 2011
- JPMA Revises Its Compliance Program GL to Ensure Good Compliance of Group Companies
April 11, 2011
- Eli Lilly Japan Confident about Becoming Top 10 Company by 2020
April 11, 2011
- Meiji, Fujirebio Terminate Joint Sales Agreement
April 11, 2011
- Korosho Calls For Restraint in Use of EN Products Due to Shortage of Ensure
April 11, 2011
- Will New Anti-AD Drugs Be Able to Take Significant Share from Aricept?
April 11, 2011
- Nipro to Create Medical Device Joint Venture in Bangladesh
April 11, 2011
- Toyama Chemical Applies for Anti-flu Drug T-750
April 11, 2011
- Full Operations Still on Hold at Utsunomiya Plant: Chugai
April 11, 2011
- Simultaneous Vaccination with 2 Vaccines Resumed from April 1
April 11, 2011
- FDA Approves Long-acting Treatment for OA Knee Pain: Seikagaku
April 11, 2011
- Korosho Asks METI to Exclude Drug Production Facilities from Planned Electricity Outages
April 11, 2011
- NICE Recommends Aricept for Mild AD
April 11, 2011
- Seikagaku Withdraws PMA for Additional Indication of Supartz in the US
April 11, 2011
- Earthquake Disrupts Production of Some Raw Materials
April 11, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…